Viridian Therapeutics Inc Forecast, price target & analysts
Viridian Therapeutics Inc Target price 2026 - Analyst rating & recommendation
Viridian Therapeutics Inc Classifications & Recommendation:
Viridian Therapeutics Inc Price Target
| Target Price | $41.31 |
| Price | $30.68 |
| Potential |
34.65%
register free of charge
|
| Number of Estimates | 18 |
|
18 Analysts have issued a price target Viridian Therapeutics Inc 2027 .
The average Viridian Therapeutics Inc target price is $41.31.
This is
34.65%
register free of charge
$52.50
71.12%
register free of charge
$19.19
37.45%
register free of charge
|
|
| A rating was issued by 24 analysts: 21 Analysts recommend Viridian Therapeutics Inc to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Viridian Therapeutics Inc stock has an average upside potential 2027 of
34.65%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.30 | 79.60 |
| 3.23% | 26,433.33% | |
| EBITDA Margin | -99,513.33% | -397.02% |
| 21.48% | 99.60% | |
| Net Margin | -89,983.33% | -436.98% |
| 17.34% | 99.51% |
17 Analysts have issued a sales forecast Viridian Therapeutics Inc 2025 . The average Viridian Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Viridian Therapeutics Inc EBITDA forecast 2025. The average Viridian Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
19 Viridian Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Viridian Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.98 | -4.23 |
| 25.05% | 6.28% | |
| P/E | negative | |
| EV/Sales | 30.88 |
19 Analysts have issued a Viridian Therapeutics Inc forecast for earnings per share. The average Viridian Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Viridian Therapeutics Inc...
Current Viridian Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Needham |
Locked
➜
Locked
|
Locked | Dec 23 2025 |
| Wedbush |
Locked
➜
Locked
|
Locked | Dec 10 2025 |
| William Blair |
Locked
➜
Locked
|
Locked | Dec 03 2025 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Nov 24 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Nov 06 2025 |
| BTIG |
Locked
➜
Locked
|
Locked | Nov 04 2025 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | Oct 21 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Needham:
Locked
➜
Locked
|
Dec 23 2025 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Dec 10 2025 |
|
Locked
William Blair:
Locked
➜
Locked
|
Dec 03 2025 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Nov 24 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Nov 06 2025 |
|
Locked
BTIG:
Locked
➜
Locked
|
Nov 04 2025 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Oct 21 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
